(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 2 May 2002 (02.05.2002)

PCT

(10) International Publication Number WO 2002/034776 A3

- (51) International Patent Classification⁷: C07K 14/81, C12N 15/15, G01N 33/53, C07K 16/38, A61K 39/395
- (21) International Application Number:

PCT/BE2001/000186

- (22) International Filing Date: 25 October 2001 (25.10.2001)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


100 53 251.9 101 10 235.6 26 October 2000 (26.10.2000) DE 2 March 2001 (02.03.2001) DE

(71) Applicant (for all designated States except US): K.U.LEUVEN RESEARCH AND DEVELOPMENT [BE/BE]; Groot Begijnhof, Benedenstraat 59, B-3000 Leuven (BE).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DECLERCK, Paul [BE/BE]; Lemingstraat 9, B-3210 Lubbeek (BE). STASSEN, Jean-Marie [DE/DE]; Joseph Ravoetstraat 5, B-3012 Leuven (DE). BLJNENS, Ann-Pascal [BE/BE]; Villerspark 5/5, B-3500 Hasselt (BE). GILS, Ann [BE/BE]; Bgm. Stani De Rijcklaan 38, B-3001 Heverlee (BE). NGO, Thu, Hoa [BE/BE]; Kerkstraat 77, B-3010 Kessel-Lo (BE).
- (74) Common Representative: K.U.LEUVEN RESEARCH AND DEVELOPMENT; Lescroart Olivier-Technology Transfer Officer, Groot Begijnhof, Benedenstraat 59, B-3000 Leuven (BE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,

[Continued on next page]

(54) Title: EPITOPES OF PAI-1



(57) Abstract: The invention belongs to the field of cardiovascular and thromboembolic diseases or cancer and related diseases. The invention relates to proteins, peptides comprising specified epitopes of plasminogen activator inhibitor type-1 (PAI-1) and nucleic acids encoding said proteins or peptides. The invention further relates to methods of screening for substances capable of inhibiting said PAI-1, substances identifiable with said method and pharmaceutical compositions comprising said substances.

